Management Philosophy and Basic Policies
The corporate philosophy of SANSHO Corporation is
to "contribute to the health and well-being of the world with cyclic phosphatidic acid (cPA).
In order to realize our corporate philosophy, we will steadily and faithfully advance our research and development activities and strive to deliver necessary medicines to the medical community as soon as possible.
Background of Business Development
SANSHO was established on January 15, 2008 with the aim of conducting a drug discovery business based on the intellectual property related to an invention by Professor Emeritus Kimiko Murofushi.
Toshiro Morohoshi, the current CEO of SANSHO, has been collaborating with Professor Emeritus of Ochanomizu University, Kimiko Murofushi since the early 2000s, and established SANSHO to develop new drugs using cyclic phosphatidic acid (cPA), which Professor Murofushi discovered in the course of her research.
Toshiro Morohoshi, the current CEO of SANSHO, has been collaborating with Professor Emeritus of Ochanomizu University, Kimiko Murofushi since the early 2000s, and established SANSHO to develop new drugs using cyclic phosphatidic acid (cPA), which Professor Murofushi discovered in the course of her research.
History
| Jan. 2008 | Establishment of the Company |
|---|---|
| Oct. 2013 | Out-licensed 2Carba cycle phosphatidic acid to Orient Europharma Co.,Ltd. in Taiwan |
| Apr. 2017 | Obtained IND from US FDA for the 2 Carba cyclic phosphatidic acid (synthetic, drug) |
| Sep. 2017 | Obtained IND from Taiwan FDA for the 2 Carba cyclic phosphatidic acid (synthetic, drug) |
| Feb. 2018 | 2Carba cyclic phosphatidic acid (synthetic form, drug) Phase I clinical trial (Phase 1/b) started in Taiwan (indication: osteoarthritis of the knee) |
| May. 2019 | Series A financing from venture capital firms |
| Jul. 2019 | Opened our research laboratory at Yokohama Venture Plaza at Tokyo Institute of Technology in Yokohama, Kanagawa Prefecture |
| Oct. 2021 | 2Carba cyclic phosphatidic acid (synthetic form, drug) Phase I clinical trial (Phase 1/b) completed in Taiwan (Indication: osteoarthritis of the knee) |
| Apr. 2022 | 2Carba cyclic phosphatidic acid (synthetic form, drug) Started joint research with the Department of Respiratory and Collagen Diseases, Graduate School of Medical and Dental Sciences, The University of Tokushima (Indication: pulmonary fibrosis) |
| May. 2022 | Moved our research laboratory to Tsukuba Founder's Plaza in Tsukuba City, Ibaraki Prefecture |
| Oct. 2022 | 2Carba cyclic phosphatidic acid (synthetic form, drug) Phase Ⅱ clinical trial (Phase Ⅱa) started in Taiwan (indication: osteoarthritis of the knee) |
As of February 21, 2024
Company Profile
| Company Name | SANSHO Co., Ltd. |
|---|---|
| Location | 【Head office】 Momijigawa Building Suite. 401 2-15-8 Nihonbashi, Chuo-ku, Tokyo 103-0027 JAPAN 【Laboratory】 Tsukuba Sogyo Plaza 203 2-1-6 Sengen Tsukuba-city, IBARAKI 305-0047 JAPAN |
| Establishment | January 15, 2008 |
| Capital stock | 59,600,000 JPY（As of March 22. 2024） |
| Total number of shares issued and outstanding | 1,035 shares (842 shares of common stock and 193 shares of Class A shares) |
| Officers | President and CEO Toshiro Morohoshi Outside Director Chi-Tai Chang |
| Science Advisory Board | Dr. Shigeyuki Wakitani Director, Kouryoukai Hospital (Orthopedic Surgeon) Dr. Koji Kawakami Professor, Kyoto University School of Medicine (Pharmacoepidemiology) Dr. Ikuko Masuda Director, Department of Rheumatology and Orthopedics, Jujo Kyoto Rehabilitation Hospital and Adjunct Lecturer, Tokyo Women's Medical University |
